全文获取类型
收费全文 | 1383篇 |
免费 | 110篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 56篇 |
妇产科学 | 4篇 |
基础医学 | 116篇 |
口腔科学 | 2篇 |
临床医学 | 264篇 |
内科学 | 595篇 |
皮肤病学 | 10篇 |
神经病学 | 12篇 |
特种医学 | 40篇 |
外科学 | 48篇 |
综合类 | 223篇 |
预防医学 | 19篇 |
眼科学 | 13篇 |
药学 | 72篇 |
中国医学 | 51篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 3篇 |
2023年 | 16篇 |
2022年 | 33篇 |
2021年 | 42篇 |
2020年 | 41篇 |
2019年 | 54篇 |
2018年 | 43篇 |
2017年 | 42篇 |
2016年 | 26篇 |
2015年 | 35篇 |
2014年 | 79篇 |
2013年 | 69篇 |
2012年 | 60篇 |
2011年 | 85篇 |
2010年 | 84篇 |
2009年 | 68篇 |
2008年 | 75篇 |
2007年 | 103篇 |
2006年 | 61篇 |
2005年 | 79篇 |
2004年 | 42篇 |
2003年 | 41篇 |
2002年 | 46篇 |
2001年 | 39篇 |
2000年 | 36篇 |
1999年 | 31篇 |
1998年 | 23篇 |
1997年 | 30篇 |
1996年 | 22篇 |
1995年 | 18篇 |
1994年 | 13篇 |
1993年 | 14篇 |
1992年 | 11篇 |
1991年 | 17篇 |
1990年 | 13篇 |
1989年 | 8篇 |
1988年 | 6篇 |
1987年 | 8篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有1527条查询结果,搜索用时 15 毫秒
11.
Vitamin B2 and flavin cofactors are transported tightly bound to immunoglobulin in human serum. We reasoned that anti-mitochondrial flavoprotein autoantibodies (alpha Fp-AB) present in the serum of patients with myocarditis and cardiomyopathy of unknown aetiology may form immunoglobulin aggregates with these serum proteins. However, immunodiffusion and Western blot assays demonstrated that the flavin-carrying proteins were not recognized by alpha Fp-AB. Apparently the flavin moiety in the native protein conformation was inaccessible to alpha Fp-AB. This conclusion was supported by the absence of an immunoreaction between the riboflavin-binding protein from egg white and alpha FP-AB. Intravenous application of vitamin B2 to rabbits immunized with 6-hydroxy-D-nicotine oxidase, a bacterial protein carrying covalently attached FAD, did not neutralize alpha Fp-AB which had been raised in the serum of the animals. FAD-carrying peptides generated from 6-hydroxy-D-nicotine oxidase by trypsin and chymotrypsin treatment were not recognized by the alpha Fp-AB, but those generated by endopeptidase Lys were. This demonstrates that the epitope recognized by alpha Fp-AB comprises, besides the flavin moiety, protein secondary structure elements. 相似文献
12.
Myocarditis: unresolved issues in diagnosis and treatment 总被引:2,自引:0,他引:2
Myocarditis is an enigmatic disease. Lymphocytic myocarditis is most commonly viral in origin. Considerable evidence suggests that myocardial damage is due to an immune-mediated mechanism rather than to direct effects of the virus itself. The presentation is variable, ranging from a clinically inapparent or relatively benign illness to acute progressive heart failure and death. Although examination of the endomyocardial biopsy specimen is the "gold standard" for the diagnosis of myocarditis there are problems with this technique, relating particularly to sampling error and histologic interpretation. Considerable evidence, both animal and human, suggests that a link between viral myocarditis and dilated cardiomyopathy does exist. There is a rational basis for the use of immunosuppressive therapy in myocarditis. Although many favorable responses have been reported with the use of these agents, the results of more definitive studies are awaited to determine the role of immunosuppressive therapy in myocarditis more clearly. Recommendations for the practical management of patients with myocarditis are made. Whenever possible, patients with this diagnosis should be entered into the ongoing NIH trial. 相似文献
13.
Ruan Zhongbao Geng Qian Ma Genshan Chen Xiangjian Zhang Jinan Cao Kejiang Ma Wenzhu 《南京医科大学学报(英文版)》2000,14(2):64-68
[1]Richardson CP, Mckenna RM, Bristow CM, et al.Report of the 1995 Word Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation, 1996,93: 841
[2]Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet, 1994,343:327
[3]Martin AB, Garson A, Perry JC, et al. Prolonged QT interval in hypertropic and dilated cardiomyopathy in children. Am Heart J, 1994,127(1):64
[4]Pye M, Quinn AC, Cobble SM. QT dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias?Br Heart J, 1994,71(5):51
[5]Berger RD, Kasper EK, Baughman KL, et al. Beat to beat QT interval variability: novel evidence for repolarization lability in ischemic and non ischemic dilated cardiomyopathy. Circulation, 1997, 96 (5):1557
[6]Wolfram G, Ulrike S, Volker M, et al. QT dispersion and arrhythmic events in idiopathic dilated cardiomyopathy. Am J Cardiol, 1997,78: 458
[7]Fei L, Goldman JH, Prasal K, et al. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J, 1996,17: 258
[8]Pan YZ, Guo NS, Xing ZF, et al. The relation between QT dispersion and ventricular arrhythmia of dilated cardiomyopathy. Chin J Inter Medi, 1996,35(11):73
[9]Galinier M, Vialette JC, Fourcade J, et al. QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology. Eur Heart J, 1998,19(7) :1054 相似文献
14.
为评价超声心动图对扩张性心肌病(DCM)患者左室舒张功能的诊断价值。方法:用超声心动图 和放射性核素显像(RNV)对20例DCM患者和20例同龄正常人的左室舒张功能进行对照分析。结果:DCM组左室 舒张功能RNV指标峰充盈率(PFR)明显降低,同对照组比较差异有显著性(P<0.05);超声指标二尖瓣血流频谱早 期充盈峰速度(νE)、晚期充盈峰速度(νA)、νA/νE等参数同对照组比较无明显差异(P>0.05),表现为“正常”。结 论:超声心动图舒张功能指标νE、νA、νA/νE不能真实反映DCM患者的左室舒张功能。 相似文献
15.
目的:探讨美托洛尔(metoprolol)治疗充血性心力衰竭(CHF)的有效性和可行性。方法:采用随机对照方法,观察经强心、利尿和血管紧张素转换酶抑制剂(ACEI)治疗仍有CHF症状的扩张型心肌病患者加用美托洛尔治疗前后循环内分泌因子和心功能状态的变化。结果:①治疗3个月时,美托洛尔组心胸比和心脏面积与对照组相比均明显缩小(分别P<001);②治疗3个月时,美托洛尔组左室射血分数(LVEF)较对照组显著增高(3735±628vs3325±646,P<001);③所有患者血浆内皮素(ET)和去甲肾上腺素(NE)水平均与LVEF呈负相关(均P<0001);④显效组患者年龄偏小,心率偏快,血浆NE,ET水平较高,和其他组相比有显著差异。结论:美托洛尔治疗CHF有效,尤其年龄偏小、心率偏快、血浆NE和ET水平较高的扩张型心肌病亚组。 相似文献
16.
17.
Tomoka Tabata Yuki Kuramoto Tomohito Ohtani Hiroshi Miyawaki Yohei Miyashita Fusako Sera Hidetaka Kioka Shuichiro Higo Yoshihiro Asano Shungo Hikoso Yasushi Sakata 《Internal medicine (Tokyo, Japan)》2022,61(13):1987
Phospholamban p.Arg14del is reported to cause hereditary cardiomyopathy with malignant ventricular tachycardia (VT) and advanced heart failure. However, the clinical courses of Japanese cardiomyopathy patients with phospholamban p.Arg14del remain uncharacterized. We identified five patients with this variant. All patients were diagnosed with dilated cardiomyopathy (DCM), developed end-stage heart failure and experienced VT requiring implantable cardioverter defibrillator discharge. Four patients survived after implantation of a left ventricular assist device (LVAD), while one patient who refused LVAD implantation died of heart failure. Based on the severe course of the disease, we propose genetic screening for phospholamban p.Arg14del in DCM patients. 相似文献
18.
M. Steinfath J. Lavicky W. Schmitz H. Scholz V. Döring P. Kalmár 《European journal of clinical pharmacology》1992,42(6):607-611
Summary Total -adrenoceptor density and 1- and 2-subtype distribution in right and left atria and in different ventricular regions from 14 failing and seven nonfailing human hearts have been compared. End-stage heart failure was due to idiopathic dilated cardiomyopathy (n=8) or ischaemic cardiomyopathy (n=6).In nonfailing hearts the total -adrenoceptor density was similar in the right and left atria and in all the ventricular regions studied (about 70 to 80 fmol/mg protein). The 1:2-adrenoceptor ratio in both nonfailing atria was similar (about 70:30%) and was significantly smaller than in the different regions of both ventricles (about 80:20%). The 1-subtype density was similar in nonfailing atria and ventricles (about 55 fmol/mg protein). The 2-subtype density was significantly higher in the right and left atrium (about 25 fmol/mg protein) than in both ventricles (about 15 fmol/mg protein).In patients with end-stage heart failure due to idiopathic dilated cardiomyopathy or ischaemic cardiomyopathy the total -adrenoceptor density was reduced by 50–60% in all regions. On the other hand, the 1- and 2-subtype distribution differed with the cause of heart failure. In patients with idiopathic dilated cardiomyopathy, the 1-adrenoceptor density was lower in all regions, but the 2-adrenoceptor density was not significantly reduced. In patients with ischaemic cardiomyopathy both 1- and 2-adrenoceptors were reduced in all regions.It is concluded that downregulation of -adrenoceptors in patients with end-stage idiopathic dilated cardiomyopathy or ischaemic cardiomyopathy occurs uniformly throughout the heart. The results support the hypothesis that changes in -adrenoceptor subtypes may be related to the cause of heart failure. 相似文献
19.
Many authors have reported noninvasive means of diagnosing anomalous left coronary artery from pulmonary artery (ALCAPA)
and differentiating ALCAPA from idiopathic dilated cardiomyopathy (DCM). Systematic evaluation using these noninvasive diagnostic
modalities is not available. To distinguish between ALCAPA and DCM using a systematic approach, we examined 23 patients with
ALCAPA (age 1 month to 23 years, median 7 months) and 23 patients with DCM (age 5 days to 16 years, median 6.6 months). Standard
12-lead electrocardiograms (ECG) and 2-dimensional (2-D) and color Doppler echocardiograms were performed. A logistic regression
model was applied using ALCAPA diagnosis as the dependent variable and ECG and echocardiographic findings as independent variables.
A scoring system was created to establish the ALCAPA diagnosis based on results from the logistic regression. On the logistic
regression, the ECG feature of QT pattern in aVL (Q wave ≥ 3 mm deep with an inverted T wave) and echocardiographic features
of right coronary artery diameter to aortic annulus ratio ≥ 0.14, increased papillary muscle echogenicity, and Doppler color
flow of LCA from aorta or pulmonary artery were the most significant differentiating features between the ALCAPA and DCM groups.
A scoring system was developed using the previous five variables and assigning a score of 1 to each variable (−1 to Doppler
color flow of LCA from aorta). The scoring system had sensitivity of 100% and specificity of 91% for ALCAPA diagnosis. Compared
with previous reported diagnostic features in differentiating ALCAPA and DCM, the scoring system had a much higher specificity
and positive predictive value. In conclusion, we selected the most useful ECG and echocardiographic features to differentiate
between ALCAPA and DCM and created a scoring system to aid clinical diagnosis. This scoring system may be useful in evaluating
children with acute congestive heart failure. 相似文献
20.
Rationale:The treatment of dilated cardiomyopathy (DCM) has recently been greatly improved, especially with the widespread use of sacubitril/valsartan (ARNI) combination therapy. We know that ARNI-like drugs can significantly improve the symptoms of heart failure with reducing ejection fraction. However, clinical studies evaluating the safety and efficacy of ARNI in DCM-associated arrhythmia are limited, and whether individuals with arrhythmia would benefit from ARNI remains controversial. In this case, we report a patient with complete left bundle branch block (CLBBB) associated with DCM whose CLBBB returned to normal after treatment with ARNI.Patient concerns:A 38-year-old man was admitted to the hospital for 20 days for idiopathic paroxysmal dyspnea. He presented with exacerbated dyspnea symptoms at night, accompanied by cough and sputum.Diagnosis:Physical examination revealed a grade 4/6 systolic murmur could be heard in the apical area of the heart and mild edema was present in both lower limbs. Laboratory examination found that the B-type natriuretic peptide was significantly increased. Echocardiography indicated left atrial internal diameter, right ventricular internal diameter, and left ventricular diastolic diameter were enlarged and ejection fraction was significantly decreased. Besides, the pulsation of the wall was diffusely attenuated. Electrocardiogram was suggestive of tachycardia and CLBBB. A diagnosis of DCM with CLBBB was considered based on a comprehensive evaluation of the physical examination, laboratory examination, echocardiography and electrocardiogram.Interventions:The patient was treated with ARNI at a dose of 50 mg (twice a day) at first, gradually increasing to the target dose (200 mg, twice a day) in the following 9 months as shown in Table Table1,1, along with metoprolol 25 mg (once a day [qd]), diuretics 20 mg (qd), and aldosterone 20 mg (qd).Table 1Specific medications used in treatment.
Open in a separate windowARNI = sacubitril/valsartan, QD = once a day.Outcomes:After treatment with ARNI during the 9-month follow-up, the patient’s symptoms improved, and CLBBB returned to normal.Lessons:Clinical studies evaluating the safety and efficacy of ARNI in DCM-associated arrhythmia are limited, and whether individuals with arrhythmia would benefit from ARNI remains controversial. This report will help to instruct the clinical treatment of DCM patients with CLBBB and the potential application of ARNI. 相似文献
Month(s) and dates after discharge | Morning (ARNI) | Night (ARNI) | Metoprolol 23.75 mg QD; diuretics (furosemide) 20 mg QD; aldosterone 20 mg QD |
---|---|---|---|
Month 1 (28/02/20–27/03/20) | 50 mg | 50 mg | |
Month 2 (27/03/20–26/04/20) | 100 mg | 50 mg | |
Month 3–4 (26/04/20–28/06/20) | 100 mg | 100 mg | |
Months 5–7 (28/05/20–29/08/20) | 150 mg | 100 mg | |
Months 8–11 (29/08/20–13/11/20) | 150 mg | 150 mg | |
Month 11–present (13/11/20–) | 200 mg | 200 mg |